Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) EPS (Weighted Average and Diluted) (2019 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.46 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 38.67% to -$0.46 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.84, a 8.97% increase, with the full-year FY2024 number at -$3.71, up 1.33% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.46 for Q3 2025 at Creative Medical Technology Holdings, up from -$2.09 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $11.18 in Q1 2021 to a low of -$4.82 in Q4 2021.
  • A 5-year average of -$0.12 and a median of -$0.5 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 228855.67% in 2021, then crashed 7770.92% in 2022.
  • Creative Medical Technology Holdings' EPS (Weighted Average and Diluted) stood at -$4.82 in 2021, then soared by 89.0% to -$0.53 in 2022, then tumbled by 125.0% to -$1.19 in 2023, then increased by 6.08% to -$1.12 in 2024, then soared by 58.93% to -$0.46 in 2025.
  • Per Business Quant, the three most recent readings for CELZ's EPS (Weighted Average and Diluted) are -$0.46 (Q3 2025), -$2.09 (Q2 2025), and $0.83 (Q1 2025).